ORMP

+ Watchlist + Portfolio

Oramed Pharmaceuticals Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.48
52-Week Range: $2.09 – $5.47
Market Cap: $183.76M
P/E (TTM): 1.09
EPS (TTM): 4.13
Dividend Yield: 5.57%

Advanced Metrics

Price/Book: 0.58
PEG Ratio: —
Return on Equity: 74.24%
Return on Assets: -3.42%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.98
Debt/Equity: 0.00
Total Debt: $733.00K
Free Cash Flow: $2.51M
Revenue Growth: —
Earnings Growth: 493.50%
Enterprise Value: $136.89M

ORMP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.70M	$1.34M	$0.00	$2.00M
Cost of Revenue	—	—	$0.00	$1.99M
Gross Profit	—	—	$0.00	$13.00K
Research & Development	$27.64M	$8.97M	$6.32M	$6.38M
Selling, General & Admin	$15.66M	$8.14M	$6.46M	$8.72M
Operating Expenses	$43.30M	$17.11M	$12.78M	$15.10M
Operating Income	-$40.60M	-$15.77M	-$12.78M	-$15.09M
EBITDA	-$37.61M	$7.32M	-$14.87M	$75.44M
Pretax Income	-$37.66M	$5.09M	-$15.92M	$75.32M
Income Tax	$100.00K	$0.00	$3.18M	$11.31M
Net Income	-$36.56M	$5.53M	-$19.06M	$64.05M
Diluted EPS	-0.94	0.14	-0.48	1.50
Diluted Shares	39.00M	40.57M	40.85M	42.42M

ORMP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$40.46M	$9.05M	$54.42M	$45.95M
Receivables	—	—	$0.00	$4.64M
Current Assets	$157.11M	$162.58M	$143.22M	$133.27M
Total Assets	$161.64M	$220.55M	$155.28M	$230.86M
Current Liabilities	$5.75M	$53.21M	$5.68M	$19.09M
Total Debt	$894.00K	$51.62M	$372.00K	$825.00K
Total Liabilities	$10.49M	$57.66M	$9.93M	$31.12M
Retained Earnings	-$163.08M	-$157.56M	-$176.62M	-$123.44M
Shareholders' Equity	$151.81M	$163.82M	$146.26M	$199.74M
Working Capital	$151.36M	$109.37M	$137.54M	$114.19M
Net Debt	—	$41.96M	—	—

ORMP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.92M	-$10.29M	-$8.41M	-$9.14M
Capital Expenditure	-$496.00K	-$254.00K	-$18.00K	-$1.93M
Free Cash Flow	-$28.41M	-$10.55M	-$8.43M	-$11.08M
Depreciation & Amortisation	$58.00K	$196.00K	$193.00K	$121.00K
Stock-Based Compensation	$11.51M	$4.21M	$4.05M	$5.99M
Investing Cash Flow	$30.21M	-$73.04M	$105.82M	$5.44M
Financing Cash Flow	$10.78M	$51.98M	-$52.04M	-$4.74M
Share Repurchases	—	$0.00	-$2.48M	-$4.74M
Net Change in Cash	$13.07M	-$31.36M	$45.37M	-$8.44M

ORMP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.00M	$0.00	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$1.99M	$0.00	$0.00	$0.00	$0.00	$0.00
Gross Profit	$13.00K	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.21M	$1.03M	$1.15M	$1.99M	$1.59M	$0.00
Selling, General & Admin	$2.31M	$1.46M	$1.27M	$3.68M	$2.06M	$2.77M
Operating Expenses	$4.51M	$2.49M	$2.43M	$5.67M	$3.66M	$2.77M
Operating Income	-$4.50M	-$2.49M	-$2.43M	-$5.67M	-$3.66M	-$2.77M
EBITDA	-$4.47M	-$2.46M	$59.48M	$9.83M	-$3.63M	-$2.73M
Pretax Income	-$7.06M	$13.13M	$59.45M	$9.80M	$49.44M	$101.59M
Income Tax	$584.00K	-$126.00K	$11.06M	-$212.00K	$11.13M	$23.43M
Net Income	-$7.64M	$13.29M	$48.40M	$10.01M	$38.31M	$78.16M
Diluted EPS	-0.19	0.31	1.13	—	0.91	1.84
Diluted Shares	41.23M	42.61M	42.77M	—	41.97M	42.50M

ORMP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$74.52M	$15.80M	$52.18M	$45.95M	$13.20M	$15.24M
Receivables	—	—	—	$4.64M	$0.00	$622.00K
Current Assets	$131.48M	$99.03M	$136.12M	$133.27M	$68.15M	$53.41M
Total Assets	$147.54M	$161.68M	$220.49M	$230.86M	$268.85M	$369.64M
Current Liabilities	$5.49M	$3.69M	$6.12M	$19.09M	$10.56M	$10.73M
Total Debt	$301.00K	$912.00K	$860.00K	$825.00K	$761.00K	$733.00K
Total Liabilities	$7.64M	$8.10M	$18.16M	$31.12M	$30.57M	$52.17M
Retained Earnings	-$184.26M	-$170.97M	-$122.58M	-$123.44M	-$85.12M	-$6.96M
Shareholders' Equity	$140.81M	$154.53M	$203.28M	$199.74M	$238.28M	$317.47M
Working Capital	$125.98M	$95.33M	$130.00M	$114.19M	$57.59M	$42.68M

ORMP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.52M	-$3.54M	-$1.63M	-$466.00K	-$2.92M	-$200.00K
Capital Expenditure	-$3.00K	-$4.00K	-$2.13M	—	-$5.00K	-$2.00K
Free Cash Flow	-$3.52M	-$3.54M	-$3.75M	-$264.00K	-$2.92M	-$202.00K
Depreciation & Amortisation	$30.00K	$30.00K	$31.00K	$30.00K	$30.00K	$31.00K
Stock-Based Compensation	$2.19M	$800.00K	$719.00K	$2.28M	$1.74M	$1.39M
Investing Cash Flow	$23.62M	-$54.85M	$38.36M	-$1.68M	-$19.49M	$4.31M
Financing Cash Flow	$0.00	-$371.00K	-$361.00K	-$4.01M	-$10.36M	-$1.95M
Dividends Paid	$0.00	$0.00	—	—	-$10.36M	-$78.00K
Share Repurchases	—	—	-$361.00K	-$4.01M	—	—
Net Change in Cash	$20.10M	-$58.76M	$36.38M	-$6.16M	-$32.77M	$2.16M

Market Snapshot

About

Oramed Pharmaceuticals Inc. is an Israeli biotechnology company developing oral drug delivery systems, primarily focused on oral insulin and other oral formulations of injectable therapies for diabetes treatment.